Halozyme Therapeutics, Inc. (HALO) Stock Price & Analysis
Halozyme Therapeutics, Inc. (HALO) closed at USD 124.54 on Thursday, October 22, 2026, down 0.23% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 124.83; the Oct 22, 2026 session ranged USD 121.66–124.72 on volume of 5,097,769 shares. Market capitalization is $14.14B, with a 52-week range of USD 61.23–125.43 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HALO.md
Key facts (HALO)
- Last four reported quarters (through Jun 30, 2026): revenue $1.66B, net income $414M (24.9% margin), free cash flow $806M (SEC filings).
- Valuation: P/E 34.2x (avg 19.3x at the last 3 fiscal year-ends), EV/EBITDA 26.2x, net debt $1.92B.
- 2 of 80 tracked superinvestors hold HALO (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 108.78 (range 78–130).
- Total return with dividends: 1Y +86.2% vs S&P 500 +14.9%; 5Y +220.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.35, revenue estimate $491M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HALO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $443M | $660M | $829M | $1.02B | $1.40B | $1.66B |
| Gross profit | $362M | $521M | $637M | $856M | $1.17B | — |
| Operating income | $276M | $268M | $338M | $551M | $469M | $597M |
| Net income | $403M | $202M | $282M | $444M | $317M | $414M |
| EPS (diluted) | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 | — |
| Free cash flow | $298M | $235M | $373M | $468M | $645M | $806M |
| Gross margin | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% | — |
| Operating margin | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% | 35.9% |
| Net margin | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% | 24.9% |
| Revenue growth | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | — |
| Cash + short-term investments | $741M | $363M | $336M | $596M | $143M | — |
| Total debt | $877M | $1.51B | $1.50B | $1.51B | $2.14B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (HALO)
P/E 34.2x · P/S 8.5x · EV/EBITDA 26.2x · EV/Sales 9.7x · P/FCF 17.5x · P/B 98.5x · FCF yield 5.70% · Earnings yield 2.93% · Net debt $1.92B · EV $16.1B
P/E at fiscal year-ends: Dec 2025 26.3x, Dec 2024 13.9x, Dec 2023 17.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (HALO)
2 of 80 tracked investors hold HALO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 0.41% | $3.0M | Added +1.4% | |
| Richard Pzena | Pzena Investment Management | <0.01% | $317K | Unchanged |
Analysts (HALO)
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 108.78 (low 78, high 130).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $105 → $130 |
| 2026-10-08 | JP Morgan | Target raised | Neutral | $70 → $78 |
| 2026-10-08 | HC Wainwright & Co. | Target raised | Buy | $115 → $130 |
| 2026-09-02 | HC Wainwright & Co. | Reiterated | Buy | $115 |
| 2026-08-08 | Leerink Partners | Upgrade | Market Perform → Outperform | $83 → $110 |
| 2026-08-07 | TD Cowen | Target raised | Buy | $96 → $105 |
| 2026-08-07 | Citizens | Target raised | Market Outperform | $92 → $93 |
| 2026-08-07 | Wells Fargo | Target raised | Equal-Weight | $75 → $95 |
| 2026-08-07 | HC Wainwright & Co. | Target raised | Buy | $95 → $115 |
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $95 |
Total return (dividends reinvested) (HALO)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +86.2% | +220.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +86.6% | +26.1% |
| Volatility (annualized) | 36.5% | 42.0% |
| Max drawdown | -24.1% (Feb 2026→Mar 2026) | -47.9% (Nov 2022→May 2023) |
Companies that name HALO in their SEC reports
| Relationship to HALO | Company | Filing | Sentence |
|---|---|---|---|
| partner | ARGENX SE (ARGX) | 20-F Mar 19, 2026 | “In February 2019, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics,” |
HALO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.35 | $2.19 | +7.3% | $490.8M | 6 |
| Next quarter (ends Dec 2026) | $2.62 | $2.55 | +2.8% | $537.6M | 6 |
| Current fiscal year (ends Dec 2026) | $8.84 | $8.12 | +8.8% | $1.88B | 6 |
| Next fiscal year (ends Dec 2027) | $10.68 | $9.91 | +7.7% | $2.10B | 5 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 124.54 |
|---|---|
| Change | ▼ 0.23% (down) |
| Previous Close | USD 124.83 |
| Open | USD 124.72 |
| Day Range | USD 121.66 – 124.72 |
| 52-Week Range | USD 61.23 – 125.43 |
| Volume | 5,097,769 shares |
| Market Cap | $14.14B |
| Exchange | NMS |
Technical Analysis (HALO)
Nexqual's technical model rates HALO "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 71.24 (overbought) |
| vs SMA50 | Above (USD 110.64) |
| MACD | 4.28 (positive) |
Analyst Ratings (HALO)
Wall Street analysts rate HALO "Buy" based on 9 analysts, with a mean price target of USD 108.78 (range USD 78–130), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 108.78 |
| High Target | USD 130 |
| Low Target | USD 78 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (HALO)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.35 |
| Revenue Estimate | $490.85M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.28 vs est 1.82 ▲ beat |
| 2026-03-31 | USD 1.6 vs est 1.52 ▲ beat |
| 2025-12-31 | USD -0.24 vs est 2.2 ▼ miss |
| 2025-09-30 | USD 1.72 vs est 1.63 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (HALO)
| Total Revenue | $1.66B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +47.70% |
| Gross Margin | +76.27% |
| Operating Margin | +59.80% |
| Profit Margin | +24.86% |
| ROE | +173.67% |
| Debt / Equity | 15.18 |
| Current Ratio | 2.71 |
| Total Cash | $231.00M |
| Total Debt | $2.18B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $806.22M (48.5% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (HALO)
Nexqual rates Halozyme Therapeutics, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Strong — Revenue +38% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 60% (last 12 months) |
| Balance Sheet | Weak — $231M cash and investments vs $2.15B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $806M (last 4 quarters to Jun 2026, SEC), 48% margin |
| Efficiency | Strong — ROE 174%, ROA 25.5% |
Ownership (HALO)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +113.77% |
| Shares Outstanding | 113.50M |
| Float | 112.19M |
| Short % of Float | +17.67% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (HALO)
Halozyme Therapeutics, Inc. is led by Helen I. Torley M.B. Ch. B., M.R.C.P., President, CEO & Director, per Nexqual as of October 23, 2026 at 09:26 UTC.
| President, CEO & Director | Helen I. Torley M.B. Ch. B., M.R.C.P. |
|---|---|
| Senior VP & CFO | Darren Snellgrove |
| President of Drug Delivery | David A. Ramsay |
| Chief Scientific Officer | Christopher Wahl |
| Chief Strategy Officer | Rhys de Callier |
Major Backers & Investors (HALO)
Notable institutional backers of Halozyme Therapeutics, Inc. include Invesco, Morgan Stanley, Boston Partners, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 2.8% |
| Morgan Stanley | 2.5% |
| Boston Partners | 2.44% |
| Bank of America Corporation | 2.41% |
| William Blair Investment Management, LLC | 2.21% |
| John Hancock Funds III-Disciplined Value Mid Cap Fund | 1.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.69% |
| Vanguard Group | 9.38% |
| State Street | 4.56% |
| Geode Capital | 2.22% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | USD 214.65 | ▲ 1.26% |
| BBIO | BridgeBio Pharma, Inc. | USD 68.12 | ▲ 0.56% |
| ASND | Ascendis Pharma A/S | USD 242.99 | ▲ 1.71% |
| SMMT | Summit Therapeutics Inc. | USD 15.55 | ▼ 1.77% |
| CORT | Corcept Therapeutics Incorporat | USD 107.5 | ▼ 7.55% |
| EXEL | Exelixis, Inc. | USD 65.31 | ▲ 1.13% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt